Almost a million Americans suffering from a debilitating intestinal inflammation known as Crohn’s Disease have found little relief from the condition in which white blood cells leave the circulation and enter nearby tissue,
resulting in pain and discomfort. Based on discoveries by a pair of Oklahoma scientists, Selexys Pharmaceuticals has created promising drugs that block the P-selectin and PSGL-1 molecules that are responsible for both Crohn’s and Sickle Cell diseases.
In this issue of i&E magazine, we profile
Selexys, which is only months away from beginning human clinical trials to prove the effectiveness and safety of its treatments for Crohn’s and Sickle Cell diseases.